RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- February 14, 2007 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that it has filed a final short form prospectus with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario. The filing is further to the January 19, 2007 announcement of an equity offering of up to US$25 million and the filing of a preliminary short form prospectus. The prospectus qualifies a public offering of (i) 30,304,000 units of the Company on a firm underwritten basis at a purchase price of US$0.33 per unit, and (ii) up to 45,455,000 additional units on a best efforts agency basis on the same terms. Each unit consists of one common share of the Company and one-half of a common share purchase warrant. Each whole warrant will entitle the holder to acquire one additional common share of the Company at a price of US$0.40 per share at any time for a period of three years from the closing of the offering.
